You can start the enrollment process for your patients using one of the Taltz contracted specialty pharmacies or through Taltz Together.

Contracted specialty pharmacies

If using a specialty pharmacy, first make sure it is on the list of Taltz contracted specialty pharmacies below. Many specialty pharmacies offer enrollment forms on their website. Submit the completed specialty pharmacy enrollment form or the Taltz enrollment form to one of the contracted specialty pharmacies. If your preferred specialty pharmacy is not included in the Taltz network, submit the enrollment form to Taltz Together for assistance. If you have questions, your Taltz sales representative will be able to assist you.

View contracted specialty pharmaciesWhite Right Arrow

Taltz Together

Download the Taltz enrollment form below.

To submit to Taltz Together, please fax the completed enrollment form to 1-844-344-8108. Taltz Together will connect patients with the appropriate contracted specialty pharmacy. Patients participating in Taltz Together will be able to choose the support services that best suit their individual needs.

Taltz Together enrollment formWhite Right Arrow

To access the list of contracted specialty pharmacies in Puerto Rico, please contact your local sales representative.


The Enhanced Taltz Clear Access Program for Commercially Insured Patients

Assuring access so your patients* can confidently get Taltz. Taltz can be authorized to ship within 2 business days after prescription

*For commercially insured patients only.

Shipment can be authorized within two business days of submitting a prescription to either a participating specialty pharmacy or Taltz Together and commercial insurance is verified; patient enrolls in the Taltz Savings Card program and schedules shipment.

Your patients can get Taltz for less than $1 per day. Download Savings Cards

Each card has a unique ID number. Please do not make copies.


ERROR: We are currently experiencing technical difficulties. We were unable to submit your information. Please try again at another time. We apologize for the inconvenience.
Thank you for downloading your Taltz Savings Card! Your download has begun. If there is a problem, try downloading again.
Thank you! Your savings card has been emailed to you. If you do not receive it, please check your spam or try emailing it again.

How does The Taltz Clear Access Program work?

Eligible patients may receive Taltz for $5 or $25 for 36 months. To learn more, please select from the below options.

Patient pays $5 per month

Your patient can access Taltz with the activated savings card.

Submit an appeal

Insurance companies may request your patients try an alternate therapy before starting Taltz. Submit an appeal and other required information, such as a Letter of Medical Necessity, to the insurance company. After an appeal your patients can still access Taltz for $5 or $25 per month.

Appeal is approved

Patient pays $5 per month

Specialty pharmacy will reach out to your office or your patient to coordinate the shipment of medication and receipt of payment.

Appeal is denied

Patient pays $25 per month

Ensure you have faxed the completed Taltz Together™ enrollment form to Taltz Together at 1-844-344-8108 so your patients receive Taltz through one of our contracted specialty pharmacies that offer a $25 per month payment.

Taltz Together identifies changes in a patient’s insurance coverage to determine if the patient qualifies for the $5 per month payment.

If your patient’s commercial insurance coverage changes, he or she will be eligible to receive Taltz for $25 per month for up to 36 months.*

*Eligibility Criteria. By using the Taltz Savings Card (“Card”), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below: Offer void where prohibited by law. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program.

Offer good for up to 36 months. $5 Monthly offer subject to a maximum annual benefit of $16,000. $25 Monthly offers subject to a monthly and annual cap of wholesale acquisition cost plus usual and customary pharmacy charges.


Taltz Together is here to provide the resources and support your patients need. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966) or enroll your patients in Taltz Together by completing the Taltz Together Enrollment Form.

Offerings include:

Insurance Investigation

Injection Training

  • Free of charge to patients and their families
  • Patients can choose either in-person or telephone training
  • Injection training videos available here

Ongoing Support

  • A personal patient resource to help answer questions or concerns
  • Help is available Monday-Friday from 8 AM to 10 PM ET

Field Reimbursement Support

The Field Reimbursement Manager is an experienced access professional who can help your patients navigate the complex access and reimbursement environment

The managers are:

  • Knowledgeable: understand Taltz Together services, access challenges, and affordability options
  • Connected: integrated with the Taltz Together call center and understand the Taltz contracted specialty pharmacy network
  • Patient Focused: committed to providing information to support patient access to Taltz

Sharps Disposal Support

  • Allows patients to safely dispose of Taltz devices. Once the container is full, your patients can mail it back and contact Taltz Together to receive another one
Indication and Important Safety Information

Psoriatic Arthritis:

Taltz is indicated for the treatment of adult patients with active psoriatic arthritis.

Plaque Psoriasis:

Taltz is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.



Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Warnings and Precautions


Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.


Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease

During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis.


Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

Adverse Reactions

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profile observed in patients with psoriatic arthritis was consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.